Congressmen Mike Michaud (R-ME), Dan Burton (R-IN) and Tim
Ryan (D-OH) wrote House Energy and Commerce calling for a hearing to examine
alleged conflicts of interest involving FDA's decision not to approve Provenge.
They said “there is reason to believe that serious ethics rules were violated
by two FDA advisory panel members.”